Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University

The 1-, 3-, and 5-year overall and tumor-free survival of the patients was estimated at 100%, 70%, and 45%, respectively.CONCLUSION: A median survival of 40 months (range: 13-62 months) was achieved in recipients of grafts from a donor with a CNS tumor and no donor-related malignant transformation was observed.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:OBJECTIVE: Liver transplantation from deceased donors with a central nervous system (CNS) malignancy has some risk of tumor transmission to the recipient.

📊

Temel Bulgular & Veri:The aim of this study was to examine and present the outcomes of liver transplantations performed using donors with a CNS tumor.METHODS: Between March 2002 and July 2017, 1990 (deceased donor: n=399, 20%; living donor: n=1591, 80%) liver transplantations were performed at the center.

💡

Sonuç & Katkı:The 1-, 3-, and 5-year overall and tumor-free survival of the patients was estimated at 100%, 70%, and 45%, respectively.CONCLUSION: A median survival of 40 months (range: 13-62 months) was achieved in recipients of grafts from a donor with a CNS tumor and no donor-related malignant transformation was observed.

🔬Tür:Laboratuvar & Saha Deneyi

📍Kapsam:2002 Verileri

⚙️Değişkenler:Alan Parametreleri

Abstract

OBJECTIVE: Liver transplantation from deceased donors with a central nervous system (CNS) malignancy has some risk of tumor transmission to the recipient. Though the risk is small, this group of donors is regarded as marginal. The use of marginal grafts may be an acceptable alternative practice in order to expand the donor pool in countries where there is a shortage of donated organs. The aim of this study was to examine and present the outcomes of liver transplantations performed using donors with a CNS tumor.METHODS: Between March 2002 and July 2017, 1990 (deceased donor: n=399, 20%; living donor: n=1591, 80%) liver transplantations were performed at the center. Of the 399 deceased donors, 17 (4.2%) had a CNS tumor. The data of donors with a CNS tumor and of recipients who survived for more than 1 month (n=11) were retrospectively reviewed. Demographic data, the grade of the CNS tumor, tumor transmission to recipient data, and survival rates were analyzed.RESULTS: Only 2 (18%) grafts were provided locally, 6 (54%) were offered to the transplantation center after all of the national centers had declined them, and 3 (37%) were made available to us by the national coordination center for patients with a documented notification of urgency. High-grade (grade III-IV) brain tumors were detected in 7 (64%) donors, while low-grade (grade I-II) tumors were found in 2 patients. The remaining 2 donors were not pathologically graded because the diagnosis was made radiologically. The 1-, 3-, and 5-year overall and tumor-free survival of the patients was estimated at 100%, 70%, and 45%, respectively.CONCLUSION: A median survival of 40 months (range: 13-62 months) was achieved in recipients of grafts from a donor with a CNS tumor and no donor-related malignant transformation was observed.

🔖

Bu Makaleye Atıf Yap

BARUT, B., OZDEMİR, F., KOC, C., ERSAN, V., KAYAALP, C., YİLMAZ, S., ISİK, B., INCE, V. (2022). Deceased donor liver transplantation from donors with central nervous system malignancy: Experience of the Inonu University. İstanbul Kuzey Klinikleri, Cilt: 4 - Sayı: 3, 213–217. https://ajindex.com/articles/551588

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

Kayaalp C, Ince V, Ersan V, Karakas S, Kahraman AS, Yilmaz S. Liver Transplantation for Hepatocellular Carcinoma at Inonu University. J Gastrointest Cancer 2017
Soyer V, Koc S, Onur A, Sarıcı B, Kayaalp C, Isık B, et al. Futility Versus Acceptability of the Use of Grafts Taken From End of Line in the National Organ-Sharing Network. Transplant Proc 2015;47:1257-61
Tolan K, Kayaalp C, Ispir M, Kirmizi S, Yilmaz S. Having a Healthy Birth With a 100-Year-Old Liver. Prog Transplant 2016;26:392-3
Dirican A, Soyer V, Koc S, Yagci MA, Sarici B, Onur A, et al. Liver Transplantation With Livers From Octogenarians and a Nonagenarian. Transplant Proc 2015;47:1323-5
The Transplantation Society of Australia and New Zeeland. Clinical Guidelines for Organ Transplantation from Deceased Donors 2017. Available at: http://www.tsanz.com.au/organallocationguidelines/documents/ClinicalGuidelinesV1.1May2017. pdf. Accessed Oct 25, 2017
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109
Zhao P, Strohl A, Gonzalez C, Fishbein T, Rosen-Bronson S, Kallakury B, et al. Donor transmission of pineoblastoma in a two-yr-old male recipient of a multivisceral transplant: a case report. Pediatr Transplant 2012;16:110-4
Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 2007;27;84:272-4
Watson CJ, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant 2010;10:1437-44
Pokorna, E and Vitko S. The fate of recipients of organs from donors with diagnosis of primary brain tumor. Transpl Int 2001;14:346-7
Chui AK, Herbertt K, Wang LS, Kyd G, Hodgeman G, Verran DJ, et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc 1999;31:1266-7
European Directorate for the Quality of Medicines & HealthCare of the Council of Europe. Guide to the quality and safety of organs for transplantation. 6th ed. Council of Europe; 2016
Advisory Committee on the Safety of Blood, Tissues and Organs. Transplanation of Organs From Deceased Donors